clinical trial · NCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Alzheimer's Disease PsychosisACP-204
brief summary
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
started
Apr 23, 2024
primary completion
Apr 1, 2029
completion
May 1, 2029
last updated
Jun 2, 2026
official title
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol